Top Stories
The CSF-1R inhibitor demonstrated a 56% response rate in Phase III, alongside improvements in pain and physical function.
The companies first entered into a deal in 2024, under which AstraZeneca gained exclusive rights to Omniose's bioconjugation platform.
The once-daily atypical antipsychotic significantly improved manic symptoms and overall illness severity versus placebo at week 3.
The Danish pharma attributed the upgrade in part to migraine drug Vyepti's continued "strong performance" in the US.
The company plans to seek FDA approval of istoglogene autogetemcel (risto-cel), formerly known as BEAM-101, by the end of the year.
Conference News
· New TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs) Phase 3 data demonstrate reduced risk of disease progression in relapsed or refractory multiple myeloma as early as second line· First r...
First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).With a median follow...
FirstWord will be speaking with a leading expert about detailed SYNCHRONIZE-CVOT results for BI and Zealand's survodutide, and how competitive survodutide is likely to be in obesity and other indications
FirstWord will be speaking with a leading dermatologist about detailed Phase III ICONIC-PsA 1 findings for J&J's Icotyde, and how the oral IL-23 inhibitor will impact practice patterns in PsA.
Boehringer Ingelheim's survodutide showcased its safety in a cardiovascular outcomes trial (CVOT), but tolerability concerns could prove to be a thorn in its side. FirstWord is polling physicians to get their take on the readout.
